Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SAN FRANCISCO, Jan. 12, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in Novo Nordisk A/S (NYSE:NVO) to the securities class action lawsuit filed in the U.S. District Court for the District of New Jersey and to the March 13, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired NVO between April 30, 2015 and October 27, 2016 and suffered over $200,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/NVO
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
After repeatedly assuring investors of sales and profit growth, NVO announced its second consecutive quarter of disappointing earnings and slashed long-term profit-growth forecasts by 50% on October 28, 2016. In addition, NVO revealed it was being investigated by the U.S. Attorney’s Office for potentially improper arrangements with pharmacy benefits managers who purchase NVO’s insulin products. This news drove the price of the Company’s ADRs down approximately 13%.
“We’re focused on NVO’s insulin--and other--pricing matters and Defendants’ growth-related statements,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding NVO should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
